<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10028110
   </pmid>
   <datecreated>
    <year>
     1999
    </year>
    <month>
     04
    </month>
    <day>
     21
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1999
    </year>
    <month>
     04
    </month>
    <day>
     21
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2005
    </year>
    <month>
     11
    </month>
    <day>
     16
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1058-4838
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       28 Suppl 1
      </volume>
      <pubdate>
       <year>
        1999
       </year>
       <month>
        Jan
       </month>
      </pubdate>
     </journalissue>
     <title>
      Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
     </title>
     <isoabbreviation>
      Clin. Infect. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.
    </articletitle>
    <pagination>
     <medlinepgn>
      S57-65
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.
     </abstracttext>
    </abstract>
    <affiliation>
     Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Joesoef
      </lastname>
      <forename>
       M R
      </forename>
      <initials>
       MR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Schmid
      </lastname>
      <forename>
       G P
      </forename>
      <initials>
       GP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hillier
      </lastname>
      <forename>
       S L
      </forename>
      <initials>
       SL
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Clin Infect Dis
    </medlineta>
    <nlmuniqueid>
     9203213
    </nlmuniqueid>
    <issnlinking>
     1058-4838
    </issnlinking>
   </medlinejournalinfo>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vaginosis, Bacterial
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    60
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1999
     </year>
     <month>
      2
     </month>
     <day>
      24
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1999
     </year>
     <month>
      2
     </month>
     <day>
      24
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1999
     </year>
     <month>
      2
     </month>
     <day>
      24
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10028110
    </articleid>
    <articleid idtype="doi">
     10.1086/514725
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

